Fulgent Genetics, Inc. Common Stock FLGT
i
Market dataready · fetched 2026-11-12T03:15:03.227Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T21:00:01.721066424Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-12T03:15:02.545662+00:00
Fulgent Genetics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 29.74 | 97.4% | 17.3% | 20.57 | 209.8% | 24.1% |
| 25Δ | 29.18 | 94.3% | 15.6% | 22.45 | 159.6% | 16.8% |
| 30Δ | 28.62 | 91.1% | 14.0% | 23.32 | 141.7% | 13.8% |
| 35Δ | 28.06 | 88.0% | 12.3% | 24.17 | 124.8% | 10.9% |
| 40Δ | 27.50 | 84.9% | 10.6% | |||
| 45Δ | 26.94 | 81.8% | 9.0% | |||
| 50Δ | 26.37 | 78.6% | 7.3% | |||
| 55Δ | 25.81 | 75.5% | 5.6% | |||
| 60Δ | 25.25 | 72.4% | 4.0% | |||
| 65Δ | 24.69 | 73.6% | 3.0% | |||
| 70Δ | 24.12 | 78.3% | 2.6% | |||
| 75Δ | 23.55 | 83.0% | 2.1% | |||
| 80Δ | 22.98 | 87.7% | 1.7% | |||
20Δ
- Pseudo strike
- 29.74
- IV
- 97.4%
- B/E move
- 17.3%
- Pseudo strike
- 20.57
- IV
- 209.8%
- B/E move
- 24.1%
25Δ
- Pseudo strike
- 29.18
- IV
- 94.3%
- B/E move
- 15.6%
- Pseudo strike
- 22.45
- IV
- 159.6%
- B/E move
- 16.8%
30Δ
- Pseudo strike
- 28.62
- IV
- 91.1%
- B/E move
- 14.0%
- Pseudo strike
- 23.32
- IV
- 141.7%
- B/E move
- 13.8%
35Δ
- Pseudo strike
- 28.06
- IV
- 88.0%
- B/E move
- 12.3%
- Pseudo strike
- 24.17
- IV
- 124.8%
- B/E move
- 10.9%
40Δ
- Pseudo strike
- 27.50
- IV
- 84.9%
- B/E move
- 10.6%
- Pseudo strike
- IV
- B/E move
45Δ
- Pseudo strike
- 26.94
- IV
- 81.8%
- B/E move
- 9.0%
- Pseudo strike
- IV
- B/E move
50Δ
- Pseudo strike
- 26.37
- IV
- 78.6%
- B/E move
- 7.3%
- Pseudo strike
- IV
- B/E move
55Δ
- Pseudo strike
- 25.81
- IV
- 75.5%
- B/E move
- 5.6%
- Pseudo strike
- IV
- B/E move
60Δ
- Pseudo strike
- 25.25
- IV
- 72.4%
- B/E move
- 4.0%
- Pseudo strike
- IV
- B/E move
65Δ
- Pseudo strike
- 24.69
- IV
- 73.6%
- B/E move
- 3.0%
- Pseudo strike
- IV
- B/E move
70Δ
- Pseudo strike
- 24.12
- IV
- 78.3%
- B/E move
- 2.6%
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- 23.55
- IV
- 83.0%
- B/E move
- 2.1%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 22.98
- IV
- 87.7%
- B/E move
- 1.7%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 52.57% | |
| 57.71% | |
| 58.43% | |
| 57.74% | |
| 53.49% | |
| 57.64% | |
| 54.69% | |
| 47.65% | |
| 56.04% | |
| 56.77% | |
| 48.50% | |
| 53.68% | |
| 95.10% | |
| 54.82% | |
| 54.73% | |
| 52.19% | |
| 59.13% | |
| 57.51% | |
| 62.72% | |
| 65.47% | |
| 66.00% | |
| 58.11% | |
| 63.38% | |
| 69.33% | |
| 69.31% | |
| 71.62% | |
| 67.71% | |
| 59.53% | |
| 65.33% | |
| 64.15% |
Diagnostics & Research
GH
Guardant Health, Inc., a precision oncology company, offers blood testing, data sets, and testing in the United States and internationally. The company is headquartered in Redwood…
More →GRAL
GRAIL, LLC is a leading biotechnology firm specializing in advanced cancer diagnostics, particularly through its innovative blood tests designed for multi-cancer early detection…
More →ICLR
ICON Public Limited Company, a clinical research organization, provides outsourced marketing and development services in Ireland, the rest of Europe, the United States and…
More →IDXX
IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal…
More →ILMN
Description unavailable
More →IMDX
OncoCyte Corporation is a precision diagnostics company in the United States and internationally. The company is headquartered in Irvine, California.
More →